• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    iTeos Therapeutics, Inc. - Common Stock (NQ: ITOS )

    7.420 +0.200 (+2.77%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,443,970
    Open 7.170
    Bid (Size) 7.200 (15)
    Ask (Size) 7.420 (2)
    Prev. Close 7.220
    Today's Range 7.090 - 7.510
    52wk Range 7.090 - 18.75
    Shares Outstanding 35,763,742
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos to Participate in Upcoming Investor Conferences
    From iTeos Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    -35.98%
    -35.98%
    1 Month
    -10.82%
    -10.82%
    3 Month
    -30.00%
    -30.00%
    6 Month
    -50.17%
    -50.17%
    1 Year
    -31.61%
    -31.61%

    More News

    Read More
    iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    The One-Minute Market Report - Sunday, Sept. 22
    Via Talk Markets
    Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
    Via Investor's Business Daily
    Topics Death
    Exposures Death
    Crude Oil Surges Over 1%; Instil Bio Shares Plunge
    Via Benzinga
    Exposures Fossil Fuels
    iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos to Participate in Upcoming Investor Conferences
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    ITOS Stock Earnings: ITeos Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Dow Jumps Over 100 Points; DNOW Posts Downbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
    From iTeos Therapeutics Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.